AstraZeneca entered a collaboration and licence agreement with CSPC Pharmaceutical potentially worth up to $18.5 billion, securing rights to develop and commercialise the latter's long-acting peptide medicines in territories outside Greater China and Taiwan. The deal, announced shortly after the UK drugmaker pledged to invest $15 billion in China through 2030, includes CSPC's once-monthly injectable weight management portfolio.
With no marketed obesity drugs in its portfolio, AstraZeneca is gradually building its pipeline through acquisitions and licensing pacts. Last year, the British drugmaker exercised its option to fully acquire SixPeaks Bio — developing muscle-sparing weight loss therapies — for up to $300 million, after having initially contributed to the biotech's debut in 2024. In 2023, AstraZeneca also inked a licensing deal worth about $2 billion for Eccogene’s investigational oral, once-daily GLP-1 receptor agonist, later dubbed AZD5004.
As part of the deal announced Friday, AstraZeneca gains ex-China rights to CSPC's weight management portfolio, comprising SYH2082 — a long-acting GLP1R/GIPR agonist advancing to Phase I testing — and three other preclinical programmes targeting obesity and weight-related conditions. The partners will also collaborate on four additional programmes leveraging CSPC's platforms.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.